Off-Label Marketing MDL Over Amgen Drugs Nixed

Law360, New York (June 18, 2009, 12:00 AM EDT) -- In a major win for Amgen Inc., a judge has dismissed with prejudice the entirety of a proposed class action by a group of health benefit plans accusing the company of illegally promoting off-label uses of its anemia drugs Epogen and Aranesp.

Judge Philip Gutierrez of the U.S. District Court for the Central District of California ruled Wednesday that the amended complaint filed by the plaintiffs did not rectify any of the deficiencies he identified when he dismissed their previous complaint in December with leave to...
To view the full article, register now.